350 rub
Journal №10 for 2012 г.
Article in number:
Vascular Endothelial Growth Factor and its Type 1 and 2 Receptors in Ovarian Tumor Patients - Serum
Keywords: vascular endothelial growth factor (VEGF) VEGF type 1 and 2 receptors (sVEGFR1 and sVEGFR2) ovarian tumors
Authors:
D.N. Kushlinskii, E.S. Gershtein, V.D. Ermilova, N.V. Levkina, I.V. Tereshkina, K.P. Laktionov, L.V. Adamyan
Abstract:
Vascular endothelial growth factor (VEGF) and its soluble type 1 and 2 receptors (sVEGFR1 and sVEGFR2) were measured by ELISA techniques in blood sera of 74 primary ovarian tumor patients (39 malignant, 11 borderline and 24 benign) and 30 control practically healthy women. Increase of serum VEGF levels in relation to control group was demonstrated for patients with all types of ovarian tumors, but the difference was significant only for ovarian cancer patients. At 70 % specificity level (cut-off value 347 пг/мл) the sensitivity of this test comprised 95 %. A significant decrease of sVEGFR2 concentration in the sera of ovarian cancer patients as compared to control and benign ovarian tumor groups was demonstrated. An increase of VEGF/sVEGFR2 and VEGF/sVEGFR1 ratios was also revealed in ovarian cancer patients as compared to control and benign ovarian tumor groups. Evaluation of the associations between the parameters studied and clinicopathologic characteristics of ovarian cancer demonstrated that the highest VEGF levels were found in patients with moderately differentiated carcinomas, FIGO stage III and unilateral tumors more than 10 cm in diameter.
Pages: 30-35
References
  1. Araujo V.R., Duarte A.B., Bruno J.B., Pinho Lopes C.A., de Figueiredo J.R.Importance of vascular endothelial growth factor (VEGF) in ovarian physiology of mammals // Zygote. 2011. P. 1-10.
  2. Gutman G., Barak V., Maslovitz S., Amit A., Lessing J.B., Geva E.Regulation of vascular endothelial growth factor-A and its soluble receptor sFlt-1 by luteinizing hormone in vivo: implication for ovarian follicle angiogenesis // Fertil. Steril. 2008. V. 89. № 4. P. 922-926.
  3. Artini P.G., Ruggiero M., Monteleone P., Carpi A., Cristello F., Cela V., Genazzani A.R. Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors // Biomed. Pharmacother. 2008. V. 62. № 6. P. 373-377.
  4. Chen H., Ye D., Xie X., Chen B., Lu W. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma // Gynecol. Oncol. 2004. V. 94. № 3. P. 630-635.
  5. Wathen K.A., Unkila-Kallio L., Isaksson R., Tiitinen A., Stenman U.H., Vuorela P.Is serum-soluble vascular endothelial growth factor receptor-1 of importance in unexplained infertility - // Acta Obstet. Gynecol. Scand. 2008. V. 87. № 7. P. 738-744.
  6. Abir R., Ao A., Zhang X.Y., Garor R., Nitke S., Fisch B. Vascular endothelial growth factor A and its two receptors in human preantral follicles from fetuses, girls, and women // Fertil. Steril. 2010. V. 93. № 7. P. 2337-2347.
  7. Molskness T.A., Stouffer R.L., Burry K.A., Gorrill M.J., Lee D.M., Patton P.E.Circulating levels of free and total vascular endothelial growth factor (VEGF)-A, soluble VEGF receptors-1 and -2, and angiogenin during ovarian stimulation in non-human primates and women // Hum. Reprod. 2004. V. 19. № 4. P. 822-830.
  8. Artini P.G., Cristello F., Monti M., Cela V., Battaglia C., D'Ambrogio G., Genazzani A.R.Vascular endothelial growth factor and its soluble receptor in ovarian pathology // Gynecol. Endocrinol. 2005. V. 21. № 1. P. 50-56.
  9. Collinson F.J., Hall G.D., Perren T.J., Jayson G.C. Development of antiangiogenic agents for ovarian cancer // Expert. Rev. Anticancer Ther. 2008. V. 8. № 1. P. 21-32.
  10. Karihtala P., Maenpaa J., Turpeenniemi-Hujanen T., Puistola U.Front-line bevacizumab in serous epithelial ovarian cancer: biomarker analysis of the FINAVAST trial // Anticancer Res. 2010. V. 30. № 3. P. 1001-1006.
  11. Chambers S.K., Clouser M.C., Baker A.F., Roe D.J., Cui H., Brewer M.A., Hatch K.D., Gordon M.S., Janicek M.F., Isaacs J.D. et al. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer // Clin. Cancer Res. 2010. V. 16. № 21. P. 5320-5328.
  12. Hata K., Watanabe Y., Nakai H., Hata T., Hoshiai H. Expression of the vascular endothelial growth factor (VEGF) gene in epithelial ovarian cancer: an approach to anti-VEGF therapy // Anticancer Res. 2011. V. 31. № 2. P. 731-737.
  13. Siddiqui G.K., Elmasry K., Wong Te Fong A.C., Perrett C., Morris R., Crow J.C., Maclean A.B.Prognostic significance of intratumoral vascular endothelial growth factor as a marker of tumour angiogenesis in epithelial ovarian cancer // Eur. J. Gynaecol. Oncol. 2010. V. 31. № 2. P. 156-159.
  14. Герштейн Е.С., Левкина Н.В., Дигаева М.А., Лактионов К.П., Терешкина И.В., Кушлинский Д.Н. Матриксные металлопротеиназы 2, 7, 9 и тканевой ингибитор матриксных металлопротеиназ 1 типа в опухолях и сыворотке крови больных новообразованиями яичников // Бюллетень экспериментальной биологии и медицины. 2010. V. 149. № 5. P. 562-565.
  15. CooperB.C., RitchieJ.M., BroghammerC.L., CoffinJ., SoroskyJ.I., BullerR.E., HendrixM.J., SoodA.K.Preoperativeserumvascular endothelial growth factor levels: significance in ovarian cancer // Clin. Cancer Res. 2002. V. 8. № 10. P. 3193-3197.
  16. Hefler L.A., Zeillinger R., Grimm C., Sood A.K., Cheng W.F., Gadducci A., Tempfer C.B., Reinthaller A. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer // Gynecol. Oncol. 2006. V. 103. № 2. P. 512-517.
  17. Mahner S., Woelber L., Eulenburg C., Schwarz J., Carney W., Jaenicke F., Milde-Langosch K., Mueller V. TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients // BMC Cancer. 2010. №. 10. Р. 139.
  18. Koukourakis M.I., Limberis V., Tentes I., Kontomanolis E., Kortsaris A., Sivridis E., Giatromanolaki A. Serum VEGF levels and tissue activation of VEGFR2/KDR receptors in patients with breast and gynecologic cancer // Cytokine. 2011. V. 53. №3. P. 370-375.